Evidence Is Only as Strong as Its Method
Evidence, not vibes. Strategy, not decks. Every study should start with a clear question and a protocol built to survive scrutiny.
The evidence hierarchy still matters.
Real-world evidence becomes persuasive when the design is explicit about its place in the evidentiary stack. Not every question requires a randomized trial. Not every dataset can support a causal claim. The discipline is matching the question to the design and naming the limits honestly.
The best RWE programs do not pretend observational data is magic. They build credibility through target trial thinking, transparent cohorts, validated phenotypes, sensitivity analyses, and a clear explanation of what would change the decision.
- 01Systematic Reviews & Meta-Analyses
The strongest synthesis when the included studies are credible, comparable, and transparent.
- 02Randomized Controlled Trials
The benchmark for causal evidence, but often less representative than the real clinical world.
- 03Prospective Cohorts
Planned real-world follow-up with predefined protocols and better operational realism.
- 04Retrospective Cohorts & Case-Control
Fast, scalable, and powerful when confounding, selection, and measurement are handled directly.
- 05Descriptive Studies
The foundation: burden, prevalence, treatment patterns, and the commercial case for deeper work.
The ladder is not a status game. It is a way to prevent overclaiming. Descriptive studies can be exactly right for burden and market understanding. Comparative effectiveness needs a different burden of proof.
Every source has an argument and a flaw.
Data selection is not procurement. It is study design. Claims, EHR, registries, patient reports, and linked datasets each answer different questions and fail in different ways.
Imperfect, but if you understand what it captures and misses, incredibly powerful.
Rich clinical detail, messy data engineering, and the frontier where NLP becomes useful.
Purpose-built for research, especially strong for rare disease and longitudinal follow-up.
Claims plus EHR plus genomics plus patient voice: difficult to combine, but useful when the sources answer the same question.
Credibility is designed.
The bar for RWE is not statistical significance. It is causal clarity, operational transparency, and interpretability for the audience that has to use the finding.
Specify eligibility, treatment strategies, time zero, follow-up, outcomes, and estimands as if a trial were being designed.
Use historical patient data carefully when conventional controls are impractical, especially in rare disease and oncology.
Generate multi-site evidence while reducing unnecessary patient-level data movement.
Name the limits before someone else does.
The credibility of a real-world study is decided less by the headline result than by how honestly it handles confounding, missingness, and selection. The strongest programs publish their assumptions and pre-commit to what would change the conclusion.
If the protocol, cohort logic, and sensitivity analyses cannot be explained cleanly to a skeptical reviewer, the evidence is not ready to carry the decision.
Let's talk evidence.
Need a partner for RWE strategy, study design, or evidence generation? The best starting point is the decision your evidence has to support.